Heart failure drug vericiguat put to the test in everyday care
NCT ID NCT06486844
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study looked at data from 500 people in Germany who started taking vericiguat for chronic heart failure with reduced ejection fraction. Researchers wanted to see how well the drug works outside of clinical trials, in routine medical care. They tracked deaths and hospitalizations to measure real-world effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vericiguat (Verquvo)
What this could lead to
If successful, this study could confirm that vericiguat works as well in everyday practice as it did in clinical trials, helping doctors better manage heart failure.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It also only looks at existing data, so it cannot prove cause and effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bayer
Wuppertal, 42096, Germany